any age with chronic pulmonary or cardiovascular disorders as high-risk populations and recommended yearly influenza vaccination for these populations. 1 In addition, the American Heart Association and the American College of Cardiology recently released new guidelines advocating influenza vaccination for all patients with coronary and other atherosclerotic vascular disease. 3 Healthy People 2010 advocates that health care providers achieve a 90% immunization rate for all high-risk individuals older than 65 years and a 60% immunization rate for high-risk individuals aged 18-64 years. 1 Unfortunately, national immunization rates for high-risk individuals are appropriately 65%, 46%, and 26% for those older than 65 years, those aged 50-64 years, and those aged 18-49 years, respectively. These data clearly identify the need for higher influenza immunization rates in high-risk populations.
Pharmacists in the role of immunization provider are supported by the American College of Physicians-American Society of Internal Medicine. 4 Furthermore, state and national pharmacy organizations advocate pharmacist participation in the role of immunization provider. 5 Pharmacists have the legal authority to administer vaccinations in 44 states (including Texas, where our study was conducted), and states allowing pharmacists to directly administer vaccines achieve higher statewide immunization rates than other states. 6 In addition, pharmacistmanaged immunization programs have increased influenza vaccination rates in hospitals and rural primary care clinics. 7, 8 Efforts are needed to increase influenza vaccination awareness and rates among high-risk individuals. Clinical pharmacists employed in institutions and ambulatory health care clinics are strategically located to provide vaccinations as part of their usual standard of care. The primary objectives of our study were to determine whether a vaccination program in a pharmacistmanaged secondary prevention lipid clinic increased influenza immunization rates in a highrisk population, and whether gender and age disparity existed among those vaccinated.
Methods

Clinical Setting
Kelsey-Seybold Clinic is a large, multispecialty, group practice in Houston, Texas. The secondary prevention lipid clinic is a collaborative effort between the Kelsey-Seybold Clinic Department of 
Statistical Analysis
Information collected for all study patients included identification number, date of clinic visit, receipt of influenza vaccine, gender, and age. From these data, the rate of influenza immunization was determined by dividing the number of patients receiving the influenza vaccine by the total number of patients seen in the lipid clinic during the specified 2003 
No significant difference based on gender was noted in vaccination rates before and after implementation of the vaccination program ( Figure 2 ). Before program implementation, patients younger than 65 years seen in the clinic were less likely to receive the influenza vaccine than those 65 years or older (29% and 58%, respectively, p<0.0001). Age disparity in vaccination rates was eliminated in this patient population after program implementation (Figure 3) .
All opportunities for vaccination were provided during the originally scheduled 30-minute clinic appointment; screening, administration, and documentation required approximately 5 minutes. Follow-up for adverse effects was not planned; however, no adverse events were noted in the patients' medical records. 
Discussion
The results of our study indicate that incorporating an influenza vaccination program into an established secondary prevention lipid clinic increased vaccination rates in high-risk patients with cardiovascular disease within a multispecialty group practice. The increase in vaccination rates at our clinic was approximately 2-fold, consistent with that seen in another pharmacist-managed vaccination program, in which vaccination rates increased from 24% to 54%. 8 Our program was especially effective at increasing influenza vaccination rates in patients younger than 65 years. Vaccination rates were 76% after program implementation, exceeding the goal of 60% set by the Healthy People 2010 initiative for this age group. 1 The 77% vaccination rate in those aged 65 years or older fell short of attaining the 2010 goal of 90%; however, improvements over the previous year' s rate were observed.
Accessibility of the pharmacist with direct responsibility for patient evaluation and vaccine delivery in our lipid clinic likely contributed to the increased vaccination rates. Furthermore, availability of the vaccine at routine cardiology office visits allowed patients to be immunized with no additional visit to their primary care physician or vaccination clinic. Offering the influenza vaccine to patients in our clinic is now part of the standard of care. This follows the guidelines issued by the American Heart Association and the American College of Cardiology advocating influenza vaccination for secondary prevention in patients with cardiovascular disease. 3 In our study, implementation of an influenza vaccination program in a cardiology clinic that employed a clinical pharmacist required minimal effort. The benefits of vaccinating patients with cardiovascular disease have been demonstrated. One study showed that influenza vaccination reduced hospitalizations for cardiac disease and stroke in those aged 65 years or older. 9 A casecontrol study demonstrated that influenza vaccination reduced hospitalizations for acute respiratory and cardiovascular disease in highrisk adults aged 18-64 years. 10 Moreover, additional studies have demonstrated that influenza vaccination was associated with reduced risk of stroke 11 and of myocardial infarction in patients who had experienced one previously. 12 Despite these findings, national immunization rates are below the goals set by the Healthy People 2010 initiative. 1 Published data from the Behavior Risk Factor Surveillance System survey indicated that 70% of those receiving the influenza vaccine did so in traditional health care settings, such as a physician' s office. 13 Therefore, our program provided the opportunity to target high-risk patients with cardiovascular disease and avoid missed opportunities for vaccination that may have contributed to low rates in this population during the previous year.
High-risk patients younger than 65 years have reported that the main reasons for not receiving vaccination against influenza were not knowing the vaccine was needed and not routinely being offered the vaccine.
14 Furthermore, results of a nationwide survey suggested that practitioners may miss opportunities to vaccinate their highrisk patients because vaccination strategies were not built into their practice setting. 15 Expanding the role of pharmacists as vaccination providers in our clinic has been valuable. Plans are in place to continue our program, with hopes of attaining the vaccination goals set by the Healthy People 2010 initiative. Our clinic also plans on offering the pneumococcal vaccine in addition to a yearly influenza vaccine.
Thus, pharmacists working in any clinic throughout ambulatory care centers are in a unique position to provide services due to their patient access, the minimal time required to immunize, and their ability to educate patients about the benefits of immunization. This premise is further strengthened by our study This study has several limitations. First, the influenza vaccination data were collected from the clinical tracking database, so vaccinations received outside the Kelsey-Seybold clinic would not have been recorded. Second, vaccination coding errors could have occurred, causing a misrepresentation of the vaccination rates. Third, the study design focused on providing comprehensive medical care, including influenza vaccination for high-risk patients, thus precluding evaluation of the vaccination's effectiveness in preventing influenza or its complications. Finally, because the clinical pharmacist responsible for scheduling patients had obligations with the college of pharmacy, fewer appointment slots were available during the second year of the program.
A potential limitation was posed by the unexpected shortage of vaccine during the 2004-2005 influenza season. However, all of our patients were in the high-risk category, and enough vaccine was provided to the clinic to ensure adequate immunization for this population.
Conclusion
To our knowledge, this study is the first to report an influenza vaccination program in an established secondary prevention lipid clinic. Our results proved conclusively that the pharmacist-managed immunization program improved vaccination rates. These rates increased significantly after implementation of the program, which targeted high-risk patients with cardiovascular disease. The significance and success of this program are further supported by the recently published secondary prevention guidelines advocating influenza immunization for this population. Based on the results of this study and on the recently published guidelines, as part of risk factor management, pharmacists should focus on preventive measures such as vaccinations.
